Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof
First Claim
Patent Images
1. A substantially pure polypeptide which is at least 60% homologous to a Helios polypeptide.
2 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are (a) Aiolos gene, Aiolos polypeptides, Aiolos homodimers, Aiolos/Ikaros heterodimers and methods of using Aiolos nucleic acids and polypeptides; (b) Helios gene, Helios polypeptides, Helios homodimers, Helios/Ikaros heterodimers, Helios/Aiolos heterodimers, and methods of using Helios nucleic acids and polypeptides; (c) Daedalos nucleic acids, Daedalos polypeptides, and other related molecules and methods of making and using the same; and (d) Ikaros regulatory elements and uses thereof.
-
Citations
18 Claims
- 1. A substantially pure polypeptide which is at least 60% homologous to a Helios polypeptide.
-
5. A purified preparation of an anti-Helios antibody.
-
8. An isolated Ikaros transcriptional control region comprising one or more Ikaros regulatory element found in a lymphoid-specific DNaseI HSS cluster selected from:
-
a 9 kb BamHI fragment of a lymphoid-specific DNaseI hypersensitive site (HSS) of the mouse or human Ikaros locus (α
cluster);
a 5.9 kb BamHI/EcoRI fragment of a lymphoid-specific DNaseI HSS of the mouse or human Ikaros locus (β
cluster);
a 5 kb EcoRI fragment of a lymphoid-specific DNaseI HSS of the mouse or human Ikaros locus (γ
cluster);
a 4.2 kb EcoRI fragment of a lymphoid-specific DNaseI HSS of the mouse or human Ikaros locus (δ
cluster);
a 11 kb BamHI fragment of a lymphoid-specific DNaseI HSS of the mouse or human Ikaros locus (ε
cluster);
a 13.5 kb EcoRI fragment of a lymphoid-specific DNaseI HSS of the mouse or human Ikaros locus (ζ
cluster);
a 3.7 kb XbaI fragment of a lymphoid-specific DNaseI HSS of the mouse or human Ikaros locus (η
cluster); and
7.5 kb BamHI fragment of a lymphoid-specific DNaseI HSS of the mouse or human Ikaros locus (θ
cluster). - View Dependent Claims (9, 10)
-
- 11. A method for treating an animal for a disorder comprising administering a therapeutically-effective amount of an Aiolos polypeptide, a cell selected for the expression of a product of the Aiolos gene, or a nucleic acid encoding an Aiolos peptide to the animal.
-
14. A method of treating a neural cell related disorder in a subject, comprising:
-
providing a subject having a neural cell related disorder; and
modulating expression, levels or activity of Daedalos in a cell of the subject, to thereby treat the disorder. - View Dependent Claims (15, 16, 17, 18)
-
Specification